Edesa positive Phase 3 ARDS data at ATS Summit

 

Anticipation of CEO's oral showcase of positive Phase 3 ARDS data at ATS Summit drives EDSA surge.

Edesa Biotech’s shares jumped on extremely elevated volume (over 9 million shares on April 27 versus typical daily volume under 400,000) after trading in the $6–7 range in prior sessions. The move reflects building momentum ahead of CEO Dr. Par Nijhawan’s selection to deliver the inaugural presentation at the ATS 2026 Respiratory Innovation Summit Oral Showcase on May 15. There, he is scheduled to present findings from the company’s Phase 3 trial of paridiprubart (EB05), an anti-TLR4 antibody for Acute Respiratory Distress Syndrome, which previously demonstrated statistically significant mortality reductions (including a 27% relative risk reduction in broader populations per February 2026 updates). This extends interest from the March 31 announcement of the invitation, recent vitiligo program progress toward mid-2026 enrollment, a modest Q1 earnings beat, analyst Buy ratings, and characteristics of a low-float microcap biotech (roughly 9 million shares outstanding) prone to rapid retail-driven moves. No new press release appeared on April 27–28, but the conference catalyst and prior positive data provided clear fuel.

https://finviz.com/quote?t=EDSA&p=d